Engflag

Fabroven

Quick links to important sections

Fabroven

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fabroven

Property Description
Active Ingredients Ascorbic Acid (Vitamin C), Butcher's Broom (Ruscus Aculeatus), Hesperidin Methylchalcone, Melilot (Melilotus Officinalis)
Form Hard Capsules (Oral)
Pharmacological Class Venotonic Agent (Phlebotonic) and Capillary Stabilizer
General Purpose Provides vascular support and aids in fluid balance
Origin Phytomedicine (Fixed-Dose Combination)

Fabroven: Definition and Pharmacological Class

Fabroven is a medicine classified as a Venotonic Agent (Phlebotonic) and Capillary Stabilizer, designed to support the structural integrity and function of the peripheral venous system. This classification highlights its use in supporting the tone of vein walls and protecting the microcirculatory network. The key botanical constituent, Ruscus Aculeatus, is used to relieve symptoms associated with minor venous circulatory disturbances and helps ease common discomfort by providing support to the body’s small blood vessels. Fabroven is a Fixed-Dose Combination (FDC) Phytomedicine, distinguishing itself by integrating multiple plant components of natural origin into a single oral preparation.

What are the Active Ingredients in Fabroven?

The core active ingredients of Fabroven are a synergistic FDC comprising standardized herbal extracts and the vascular-supportive vitamin Ascorbic Acid. Specifically, the formulation includes extracts from Butcher's Broom (Ruscus Aculeatus) and Melilot (Melilotus Officinalis), along with the bioflavonoid Hesperidin Methylchalcone. The Ruscogenins in Butcher's Broom are included for their venotonic effects. Preparations containing Ruscus extracts are used to provide symptomatic relief by improving overall venous function and supporting vein wall function.

General Purpose and Vascular Benefit

The general purpose of this medicine is to provide comprehensive vascular support by addressing the integrity and function of the entire network of veins and capillaries. The ingredients, which are presented as Hard Capsules for oral use, work to maintain the integrity of vessel walls and enhance effective fluid clearance through improved Lymphatic Drainage. The formulation is recognized for assisting patients experiencing typical issues like the feeling of heavy or tired legs, providing targeted support against compromised venous and lymphatic function.

Regulatory References

  1. European Medicines Agency (EMA)
  2. EMA conclusion on Ruscus Aculeatus

What side effects are possible with Fabroven?

Possible Side Effects and Safety Information

The safety profile for Fabroven is based on the official regulatory documentation, primarily for its key herbal constituent, Ruscus aculeatus, which is often classified as a traditional herbal medicinal product. The information below reflects adverse reactions and safety statements strictly as defined in government regulatory sources, such as the European Medicines Agency (EMA) and national health authorities.

Adverse Reaction Profile

Adverse reactions documented in official labeling typically pertain to Gastrointestinal disorders. These effects may include nausea, general gastrointestinal complaints, and diarrhea. Less frequent occurrences, reported in rare cases, include stomach complaints and queasiness. A more specific, though rare, gastrointestinal effect noted is lymphocytic colitis.

For many of these undesirable effects, the frequency classification in regulatory documents is often designated as Not known. This reflects the limitations in data collection for traditional herbal medicinal products and should not be interpreted as a low frequency. No adverse reactions are officially classified as Serious Adverse Reactions in the regulatory documents for the oral product.

Population-Specific Safety Considerations and Restrictions

Hypersensitivity (allergy) to any of the active substances (Ascorbic Acid, Butcher's Broom, Hesperidin Methylchalcone, or Melilot) or any other component is an absolute Contraindication for use, as defined in official regulatory labels.

Regulatory documentation also defines restrictions for specific patient groups:

  • Pregnancy and Lactation: Use is not recommended due to the absence of sufficient data to establish safety during these periods.
  • Children and Adolescents: Use in individuals under 18 years of age is not recommended as safety has not been established due to a lack of adequate data.

The regulatory safety profile is structured to establish clear boundaries for use by classifying the risk to specific populations as unestablished and listing hypersensitivity as a definitive restriction.

Overdose and Emergency Response

Fabroven Overdose and When to Seek Help

This section summarizes information concerning Fabroven overdose, based exclusively on official regulatory documentation.

Documented Overdose Manifestations

Overdose presentations typically involve exaggerated pharmacological effects and toxicity affecting major organ systems. Documented signs include significant central nervous system (CNS) depression, presenting as severe confusion, altered mental status, and profound sedation. Cardiovascular manifestations, such as sinus tachycardia and hypotension, are also officially documented. Gastrointestinal symptoms, including nausea and vomiting, may accompany acute toxicity.

Serious Outcomes and Emergency Action

Official labeling identifies severe or life-threatening complications that require immediate intervention. These include severe cardiac arrhythmias, refractory hypotension, respiratory arrest, and the potential for status epilepticus or generalized seizures. Immediate medical attention must be sought for any suspected or confirmed Fabroven overdose, regardless of the severity of current symptoms, as stated in regulatory guidelines.

Management and Monitoring

Management is primarily supportive and symptomatic, focusing on stabilizing the patient’s clinical condition. The regulatory documentation notes that no specific antidote for Fabroven is currently established. Interventions involve continuous monitoring of vital signs and cardiac function (ECG), maintenance of a patent airway, and managing any complications, such as treating hypotension with intravenous fluids or administering anticonvulsants for seizures. Special consideration is noted for pediatric patients and individuals with pre-existing hepatic or renal impairment due to potential differences in drug clearance and toxicity progression.

Therapeutic Uses of Fabroven

What Fabroven Treats: Main Uses and Benefits

Fabroven is used in clinical settings where discomfort is driven by symptoms that interfere with daily functioning. The primary component, Ruscus aculeatus, is commonly used in contexts involving symptomatic discomfort related to minor venous disturbances and hemorrhoids. This component is relevant in conditions involving episodic or fluctuating manifestations.

It is applied across therapeutic domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive. This includes addressing functional symptoms of Chronic Venous Insufficiency (CVI), such as the persistent feeling of heavy legs, tiredness, and aching, as well as managing localized temporary swelling (edema) in the ankles. It is also used during acute symptomatic episodes of hemorrhoidal disease.

“It aims to provide supportive relief when symptoms interfere with routine activities, and may help patients cope with symptom fluctuations.”

Fabroven may assist with easing the overall symptom load during periods of heightened symptoms, offering symptomatic assistance during challenging phases.

Quick Fact: Relief for Venous and Microcirculatory Symptoms

The medicine is applied in scenarios where symptoms related to heightened physiological activity create noticeable functional strain, and may assist with managing both chronic lower-limb discomfort and acute anal venous episodes.

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Fabroven

Eligibility for Fabroven, an oral phytomedicine, is strictly limited to the Adult population, as the medicine is explicitly not indicated for use in children and adolescents. Regulatory documents establish clear prohibitions for specific populations, primarily driven by the presence of Ascorbic Acid (Vitamin C) in the formulation.

Populations for whom use is contraindicated
Individuals with known hypersensitivity to any active substance or excipient.
Patients with iron storage disorders (e.g., thalassemia, hemochromatosis, or sideroblastic anemia).

Condition-Specific and Physiological Restrictions

Use is restricted in individuals with a history of oxalate kidney stones due to the presence of Ascorbic Acid, which carries a documented risk of stone formation at higher doses. Regarding reproductive health, the official labeling mandates that the medicine should not be used during breastfeeding and recommends avoidance during pregnancy as a precautionary measure. Use is entirely governed by these specific label-based limitations and exclusions.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The officially documented interaction profile for Fabroven is primarily defined by the Ascorbic Acid component of the fixed-dose combination, as regulatory monographs for the herbal constituents (Ruscus aculeatus and Melilotus officinalis) state either no reported interactions or no available data.

Documented Exposure-Modifying Interactions

The Ascorbic Acid component has been documented to engage in pharmacokinetic interactions that modify the plasma levels and activity of co-administered medicines, as stated in regulatory prescribing information. The mechanism involves two primary patterns:

  • Urine pH Alteration: Ascorbic Acid may cause the acidification of the urine, which is documented to decrease the serum levels and alter the excretion of certain drugs, such as Amphetamine. This also affects the clearance of other drugs sensitive to changes in urine pH (e.g., Fluphenazine).
  • Activity Reduction: Ascorbic Acid is documented to decrease the activity of specific antibiotics, including Erythromycin, Kanamycin, Streptomycin, Doxycycline, and Lincomycin. Furthermore, it is documented to inactivate the antineoplastic agent Bleomycin in vitro.

Population-Specific Interaction Caution

Official regulatory documents include a specific, population-based interaction caution for the Ascorbic Acid component regarding an increased risk of severe hemolysis in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency.

Mechanism of Action

How Fabroven Works

The mechanism of action is a multi-target approach focusing exclusively on the structural integrity, tone, and fluid clearance capabilities of the peripheral venous and microcirculatory systems.

Modulating Venous Tone and Structural Integrity

The active ingredients enhance signaling at alpha1-adrenergic receptors on venous smooth muscle, which increases venous tone and reduces venous capacity. This mechanism is supported by Ascorbic Acid acting as an essential cofactor for enzymes that synthesize stable collagen, thereby structurally reinforcing the vessel walls and microvascular basement membrane to increase mechanical stability. This action facilitates blood propulsion back toward the heart, influencing the overall pressure gradient and vascular conformation.

Stabilizing Capillary Permeability and Fluid Dynamics

Components act to stabilize endothelial cell junctions within the smallest blood vessels, which limits the filtration of plasma fluid and proteins into the surrounding interstitial space, directly reducing the rate of leakage and promoting regulated microcirculatory fluid exchange. This mechanism is essential for influencing the accumulation rate of interstitial fluid and regulating fluid distribution in the periphery.

Enhancing Lymphatic Clearance Mechanisms

Specific metabolites stimulate the contractility of the smooth muscle within the lymphatic vessels (lymphangions), which modulates the functional pumping characteristics of the lymphatic vessels. This action accelerates the drainage of interstitial fluid and extravasated proteins, influencing the accumulation of interstitial fluid in the periphery and contributing to the overall re-establishment of physiological fluid homeostasis.

Dosage and Administration Information

Fabroven is administered via the oral route as a Hard Capsule, a fixed-dose combination phytomedicine intended for daily use in adults. The administration pattern is delineated by two distinct dosing regimens, each tied to the condition being managed.

Administration Details and Frequency

The administration method requires that the capsule be taken whole and swallowed with a glass of water. The medication may be taken at the start of a meal if gastric discomfort is experienced. Due to the presence of Ascorbic Acid in the formulation, the dose is typically not taken after 4 p.m.

Duration and Dosing Regimens

For the long-term management of symptoms related to venous circulation disorders, the standard daily regimen is 2 to 3 capsules. The general pattern of use for this application involves a prolonged course, typically lasting 2 to 3 months.

A distinct, short-term, higher-dose schedule applies to the management of acute symptomatic hemorrhoidal crisis. For this specific indication, the required dose is increased to 4 to 5 capsules daily. This elevated regimen is restricted to a short-term use pattern, and the treatment duration should not exceed one week. The procedural structure of use is therefore defined by the numerical dosage ranges and the time-based constraints.

Recent Clinical Evidence

The research base for this fixed-dose combination medicine has been applied in studies exploring outcomes related to physical discomfort in conditions marked by functional limitations. The primary evidence is derived from Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews for the functional symptoms of Chronic Venous Insufficiency (CVI).

Studies monitored changes related to patient-reported outcomes describing perceived discomfort, such as scores for leg pain, heaviness, and fatigue. Research also examined objective outcomes related to fluid imbalance, such as measures of lower limb fluid accumulation (edema). Findings describe patterns observed in the studies related to measured differences in both subjective symptoms and objective swelling. The results apply only to the adult populations studied, and research does not determine whether an individual will respond similarly.

For acute or disruptive episodes of hemorrhoidal disease, studies were conducted during periods of increased symptom activity, focusing on short-term symptom changes (e.g., pain and swelling). Data show patterns related to changes in symptom scores over the very short term in adult populations, but certainty remains low for long-term observation.

Study Limitations and Uncertainty

The overall evidence landscape primarily includes studies examining short-term symptom patterns, with main clinical trials typically lasting only 8 to 12 weeks. Long-term effects are not fully established, and there is limited information for long-term outcomes or the persistence of measured changes after the treatment period concludes. Data for certain groups, such as pediatric populations, those who are pregnant, or patients with advanced disease, remain insufficient. The evidence quality varies across studies, and many questions regarding chronic condition management are still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Fabroven (FAQ)

Q: Are there any known long-term side effects associated with taking Fabroven?

A: Studies and official information indicate that the long-term effects are not fully established for this medicine. The main clinical trials typically focused on short-term symptom patterns, often lasting only 8 to 12 weeks. Because of this, there is limited official information regarding outcomes following prolonged use.

Q: Does Fabroven carry a Black Box Warning, and what does that mean?

A: Official regulatory documents for the oral product do not classify any adverse reactions as Serious Adverse Reactions. These severe reactions are typically associated with the highest level of regulatory warning. The lack of this classification indicates that the most severe adverse reaction category is not listed on the medicine's label.

Q: What is the regulatory status of Fabroven in major countries like the US or EU?

A: The key botanical constituent of Fabroven is classified by the European Medicines Agency (EMA) as a traditional herbal medicinal product. This classification indicates that its use is supported by evidence of long-standing traditional use for relieving symptoms associated with minor venous circulatory disturbances.

Q: Are there different formulations of Fabroven available?

A: According to official product descriptions, Fabroven is consistently produced as a Hard Capsule. This formulation is intended for the oral route of administration. Regulatory documents do not indicate the availability of other forms, such as liquids or creams.

Q: Is it common for Fabroven to cause headaches or nausea in new users?

A: Official product information states that gastrointestinal complaints, such as nausea and general stomach discomfort, are documented adverse reactions for this medicine. However, the official frequency for these effects is often designated as "Not known," meaning a reliable estimate of how common they are is unavailable in regulatory documents. Headaches are not listed in the documented adverse reaction profile.

Q: How quickly can a person generally expect Fabroven to start working?

A: Official documents for the active ingredients suggest a time frame for the initial evaluation of effects. Regulatory documents mention that if symptoms of minor circulatory disturbances persist or worsen, patients are generally advised to consult a healthcare provider. The regulatory information does not specify an exact number of hours or days for symptomatic relief to begin.

Q: Can Fabroven cause digestive issues like diarrhea or constipation?

A: Official regulatory documentation includes diarrhea and general gastrointestinal complaints among the documented adverse reactions. Constipation is not listed in the product’s official adverse reaction profile.

Q: What specific groups of people were excluded from the clinical research for Fabroven?

A: Regulatory documents indicate that data to establish the safety and effectiveness of Fabroven is officially insufficient for several groups. These include pediatric patients (under 18), pregnant individuals, and those with advanced forms of the disease. The lack of adequate data is the established rationale for regulatory documents to state that use is not recommended in these populations.

Q: Does Fabroven require any special tests or monitoring while taking it?

A: Official documentation includes a specific safety caution for patients with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency. In this population, the Ascorbic Acid component may increase the risk of severe hemolysis, which is the destruction of red blood cells. The application of this caution depends on a patient’s individual health status, and any necessary monitoring is assessed by a healthcare provider.

Q: Is Fabroven safe for people with known kidney problems?

A: Official eligibility documents list a specific restriction for patients with a history of oxalate kidney stones. This is due to the Ascorbic Acid component, which carries a documented risk of stone formation at higher doses. General kidney impairment or disease is not listed as a specific contraindication in the official product labeling.

Q: What is the difference between Fabroven and a placebo in clinical studies?

A: Research into the medicine's key constituent has described measurable differences between the active treatment group and the placebo group. Specifically, studies observed patterns where objective measures, such as lower limb swelling, were reduced to a greater extent in the group taking the active constituent compared to the group receiving a placebo.

How should Fabroven be stored and disposed of?

Official Storage and Disposal Requirements

The following rules for storing and disposing of Fabroven hard capsules are based on official regulatory documentation.

Storage & Disposal Constraint Regulatory Requirement
Temperature Limit Do not store above 25 °C
Protection Requirement Store in the original packaging to protect from moisture
Child Safety Keep this medicine out of the sight and reach of children
Stability Rule Do not use the medicine after the stated expiry date (EXP)

Disposal Instructions:

Medicines must not be disposed of via wastewater or household waste. Unused or expired Fabroven capsules and their packaging should be returned to a designated SIGRE collection point at the pharmacy. This official procedure ensures proper pharmaceutical waste handling and helps protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fabroven found in:

A-Z Index: